Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L V Rubinstein

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Gynecologic Oncology|April 1, 1996
Vaginal clear cell adenocarcinoma in the United StatesE L Trimble, L V Rubinstein, H R Menck, et al.
Cancer Research|July 15, 1994
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosoureaJ Plowman, W R Waud, A D Koutsoukos, et al.
Statistics in Medicine|September 30, 1994
A comparison of two phase I trial designsE L Korn, D Midthune, T T Chen, et al.
Statistics in Medicine|March 15, 1994
Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: predicting biochemical mechanism of actionA D Koutsoukos, L V Rubinstein, D Faraggi, et al.
Journal of the National Cancer Institute|July 4, 1990
Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell linesL V Rubinstein, R H Shoemaker, K D Paull, et al.
British Journal of Cancer|May 18, 2001
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trialsJ I Johnson, S Decker, D Zaharevitz, et al.
Stem Cells (Dayton, Ohio)|January 1, 1994
Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's Drug Discovery Program for Cancer and AIDSJ N Weinstein, T Myers, J Buolamwini, et al.
Journal of the National Cancer Institute|June 17, 1992
Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinomaM Sznol, J W Clark, J W Smith, et al.
Cancer Research|June 1, 1992
Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screeningL Wu, A M Smythe, S F Stinson, et al.
Science (New York, N.Y.)|October 16, 1992
Neural computing in cancer drug development: predicting mechanism of actionJ N Weinstein, K W Kohn, M R Grever, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Gynecologic Oncology|April 1, 1996
Vaginal clear cell adenocarcinoma in the United StatesE L Trimble, L V Rubinstein, H R Menck, et al.
Cancer Research|July 15, 1994
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosoureaJ Plowman, W R Waud, A D Koutsoukos, et al.
Statistics in Medicine|September 30, 1994
A comparison of two phase I trial designsE L Korn, D Midthune, T T Chen, et al.
Statistics in Medicine|March 15, 1994
Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: predicting biochemical mechanism of actionA D Koutsoukos, L V Rubinstein, D Faraggi, et al.
Journal of the National Cancer Institute|July 4, 1990
Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell linesL V Rubinstein, R H Shoemaker, K D Paull, et al.
British Journal of Cancer|May 18, 2001
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trialsJ I Johnson, S Decker, D Zaharevitz, et al.
Stem Cells (Dayton, Ohio)|January 1, 1994
Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's Drug Discovery Program for Cancer and AIDSJ N Weinstein, T Myers, J Buolamwini, et al.
Journal of the National Cancer Institute|June 17, 1992
Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinomaM Sznol, J W Clark, J W Smith, et al.
Cancer Research|June 1, 1992
Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screeningL Wu, A M Smythe, S F Stinson, et al.
Science (New York, N.Y.)|October 16, 1992
Neural computing in cancer drug development: predicting mechanism of actionJ N Weinstein, K W Kohn, M R Grever, et al.
Pageof 3